• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞因子介导的信号通路失调在多发性骨髓瘤发病机制中的作用。

Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.

机构信息

Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha 3050, Qatar.

Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL 60515, USA.

出版信息

Int J Mol Sci. 2020 Jul 15;21(14):5002. doi: 10.3390/ijms21145002.

DOI:10.3390/ijms21145002
PMID:32679860
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7403981/
Abstract

Multiple myeloma (MM) is a hematologic disorder of B lymphocytes characterized by the accumulation of malignant plasma cells (PCs) in the bone marrow. The altered plasma cells overproduce abnormal monoclonal immunoglobulins and also stimulate osteoclasts. The host's immune system and microenvironment are of paramount importance in the growth of PCs and, thus, in the pathogenesis of the disease. The interaction of MM cells with the bone marrow (BM) microenvironment through soluble factors and cell adhesion molecules causes pathogenesis of the disease through activation of multiple signaling pathways, including NF-κβ, PI3K/AKT and JAK/STAT. These activated pathways play a critical role in the inhibition of apoptosis, sustained proliferation, survival and migration of MM cells. Besides, these pathways also participate in developing resistance against the chemotherapeutic drugs in MM. The imbalance between inflammatory and anti-inflammatory cytokines in MM leads to an increased level of pro-inflammatory cytokines, which in turn play a significant role in dysregulation of signaling pathways and proliferation of MM cells; however, the association appears to be inadequate and needs more research. In this review, we are highlighting the recent findings on the roles of various cytokines and growth factors in the pathogenesis of MM and the potential therapeutic utility of aberrantly activated signaling pathways to manage the MM disease.

摘要

多发性骨髓瘤(MM)是一种 B 淋巴细胞血液系统疾病,其特征是骨髓中恶性浆细胞(PC)的积累。异常浆细胞过度产生异常单克隆免疫球蛋白,还刺激破骨细胞。宿主的免疫系统和微环境对 PC 的生长至关重要,因此对疾病的发病机制也至关重要。MM 细胞通过可溶性因子和细胞黏附分子与骨髓(BM)微环境相互作用,通过激活包括 NF-κβ、PI3K/AKT 和 JAK/STAT 在内的多种信号通路,导致疾病的发病机制。这些被激活的通路在抑制 MM 细胞凋亡、持续增殖、存活和迁移方面发挥着关键作用。此外,这些通路还参与了 MM 对抗肿瘤药物的耐药性的产生。MM 中促炎细胞因子和抗炎细胞因子之间的失衡导致促炎细胞因子水平升高,反过来又在信号通路失调和 MM 细胞增殖中发挥重要作用;然而,这种关联似乎还不够充分,需要更多的研究。在这篇综述中,我们强调了各种细胞因子和生长因子在 MM 发病机制中的作用的最新发现,以及异常激活的信号通路在管理 MM 疾病方面的潜在治疗用途。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b5/7403981/5ddd6aa7f543/ijms-21-05002-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b5/7403981/98981d6de495/ijms-21-05002-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b5/7403981/ef097ff4beea/ijms-21-05002-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b5/7403981/5ddd6aa7f543/ijms-21-05002-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b5/7403981/98981d6de495/ijms-21-05002-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b5/7403981/ef097ff4beea/ijms-21-05002-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b5/7403981/5ddd6aa7f543/ijms-21-05002-g003.jpg

相似文献

1
Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.细胞因子介导的信号通路失调在多发性骨髓瘤发病机制中的作用。
Int J Mol Sci. 2020 Jul 15;21(14):5002. doi: 10.3390/ijms21145002.
2
The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.骨髓微环境在多发性骨髓瘤中恶性浆细胞生长和发育中的作用。
Int J Mol Sci. 2021 Apr 24;22(9):4462. doi: 10.3390/ijms22094462.
3
[Cytokine profiles of multiple myeloma and Waldenström macroglobulinemia].[多发性骨髓瘤和华氏巨球蛋白血症的细胞因子谱]
Klin Onkol. 2014;27(1):18-23. doi: 10.14735/amko201418.
4
Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.多发性骨髓瘤的分子发病机制:染色体畸变、基因表达变化、细胞因子网络及骨髓微环境
Recent Results Cancer Res. 2011;183:39-86. doi: 10.1007/978-3-540-85772-3_3.
5
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.将托法替尼重新用于骨髓瘤治疗以逆转骨髓微环境的促生长作用。
Haematologica. 2018 Jul;103(7):1218-1228. doi: 10.3324/haematol.2017.174482. Epub 2018 Apr 5.
6
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.缺氧诱导因子-1α(HIF-1α)的抑制作用阻断了多发性骨髓瘤浆细胞与肿瘤微环境之间的相互作用。
Exp Cell Res. 2014 Nov 1;328(2):444-55. doi: 10.1016/j.yexcr.2014.09.018. Epub 2014 Sep 26.
7
Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.破骨细胞在多发性骨髓瘤中的免疫抑制作用:程序性细胞死亡配体 1 的作用。
Front Immunol. 2018 Aug 10;9:1822. doi: 10.3389/fimmu.2018.01822. eCollection 2018.
8
Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.五聚素 3(PTX3)抑制多发性骨髓瘤患者骨髓中浆细胞/基质细胞的串扰。
J Pathol. 2013 Jan;229(1):87-98. doi: 10.1002/path.4081. Epub 2012 Oct 1.
9
Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.骨髓瘤浆细胞通过刺激间充质基质细胞的增殖来改变骨髓微环境。
Haematologica. 2014 Jan;99(1):163-71. doi: 10.3324/haematol.2013.090977. Epub 2013 Aug 9.
10
Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.骨髓微环境中的细胞外囊泡相互作用:对多发性骨髓瘤的影响
Oncotarget. 2016 Jun 21;7(25):38927-38945. doi: 10.18632/oncotarget.7792.

引用本文的文献

1
Prognosis of multiple myeloma patients based on histopathological evaluation of bone marrow.基于骨髓组织病理学评估的多发性骨髓瘤患者的预后
Caspian J Intern Med. 2025 Jun 23;16(3):562-569. doi: 10.22088/cjim.16.3.562. eCollection 2025 Summer.
2
Development and validation of a multiple myeloma diagnostic model based on systemic lupus erythematosus-associated genes and identification of specific genes.基于系统性红斑狼疮相关基因的多发性骨髓瘤诊断模型的建立与验证及特定基因的鉴定
Discov Oncol. 2025 May 18;16(1):803. doi: 10.1007/s12672-025-02555-7.
3
BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects.

本文引用的文献

1
Potential Therapeutic Roles of Exosomes in Multiple Myeloma: A Systematic Review.外泌体在多发性骨髓瘤中的潜在治疗作用:一项系统综述
J Cancer. 2019 Oct 15;10(24):6154-6160. doi: 10.7150/jca.31752. eCollection 2019.
2
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者(ICARIA-MM):一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
3
多发性骨髓瘤中靶向BCMA的疗法:进展、挑战与未来前景
Med Oncol. 2025 May 8;42(6):204. doi: 10.1007/s12032-025-02753-x.
4
A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma.硼替佐米耐药多发性骨髓瘤中循环miRNA生物标志物的预后、诊断和治疗的主题分析
SAGE Open Med. 2025 Apr 26;13:20503121251328486. doi: 10.1177/20503121251328486. eCollection 2025.
5
Multiple myeloma: signaling pathways and targeted therapy.多发性骨髓瘤:信号通路与靶向治疗。
Mol Biomed. 2024 Jul 4;5(1):25. doi: 10.1186/s43556-024-00188-w.
6
Identification of biomarkers in multiple myeloma: A comprehensive study combining microarray analysis and Mendelian randomization.多发性骨髓瘤的生物标志物鉴定:结合微阵列分析和孟德尔随机化的综合研究。
J Cell Mol Med. 2024 Jun;28(12):e18504. doi: 10.1111/jcmm.18504.
7
Targeted therapy for multiple myeloma: an overview on CD138-based strategies.多发性骨髓瘤的靶向治疗:基于CD138策略的概述
Front Oncol. 2024 Apr 9;14:1370854. doi: 10.3389/fonc.2024.1370854. eCollection 2024.
8
Liposome-encapsulated progesterone efficiently suppresses B-lineage cell proliferation.脂质体包裹的孕酮能有效抑制B系细胞增殖。
Biochem Biophys Rep. 2024 Apr 11;38:101710. doi: 10.1016/j.bbrep.2024.101710. eCollection 2024 Jul.
9
Bioinformatics-driven identification of prognostic biomarkers in kidney renal clear cell carcinoma.生物信息学驱动的肾透明细胞癌预后生物标志物鉴定
Front Nephrol. 2024 Apr 4;4:1349859. doi: 10.3389/fneph.2024.1349859. eCollection 2024.
10
A DNA origami device spatially controls CD95 signalling to induce immune tolerance in rheumatoid arthritis.DNA 折纸装置空间控制 CD95 信号诱导类风湿关节炎免疫耐受。
Nat Mater. 2024 Jul;23(7):993-1001. doi: 10.1038/s41563-024-01865-5. Epub 2024 Apr 9.
The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma.
微小RNA在多发性骨髓瘤发病机制中的作用与功能
Cancers (Basel). 2019 Nov 6;11(11):1738. doi: 10.3390/cancers11111738.
4
Evaluation of the safety and efficacy of daratumumab outside of clinical trials.评估达雷妥尤单抗在临床试验之外的安全性和疗效。
Int J Hematol. 2019 Jun;109(6):665-672. doi: 10.1007/s12185-019-02648-4. Epub 2019 Apr 8.
5
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.用AMG 424靶向多发性骨髓瘤,AMG 424是一种新型抗CD38/CD3双特异性T细胞招募抗体,针对细胞毒性和细胞因子释放进行了优化。
Clin Cancer Res. 2019 Jul 1;25(13):3921-3933. doi: 10.1158/1078-0432.CCR-18-2752. Epub 2019 Mar 27.
6
Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.来那度胺联合地塞米松治疗复发难治性多发性骨髓瘤患者——来自捷克骨髓瘤单克隆丙种球蛋白病登记处的数据分析。
Neoplasma. 2019 May 23;66(3):499-505. doi: 10.4149/neo_2018_180824N644. Epub 2019 Feb 14.
7
Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options.异常的 Wnt 信号通路在多发性骨髓瘤中的作用:分子机制和靶向治疗选择。
Leukemia. 2019 May;33(5):1063-1075. doi: 10.1038/s41375-019-0404-1. Epub 2019 Feb 15.
8
Once-weekly twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.每周一次、每周两次卡非佐米治疗新诊断多发性骨髓瘤患者:两项 I/II 期研究的汇总分析。
Haematologica. 2019 Aug;104(8):1640-1647. doi: 10.3324/haematol.2018.208272. Epub 2019 Feb 7.
9
Immunotherapy in myeloma: how far have we come?骨髓瘤的免疫疗法:我们已经取得了多大进展?
Ther Adv Hematol. 2019 Jan 18;10:2040620718822660. doi: 10.1177/2040620718822660. eCollection 2019.
10
A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting.美国社区肿瘤环境中卡非佐米与其他全身性多发性骨髓瘤化疗药物的真实世界比较分析。
Ther Adv Hematol. 2019 Jan 11;10:2040620718816699. doi: 10.1177/2040620718816699. eCollection 2019.